SCHEMBL1607692

SCHEMBL1607692

[c]1sccc1N1CCOCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.41
EP300 Q09472 1/20 0.39
KAT2B Q92831 1/20 0.39
ALDH1A1 P00352 5/20 0.37
NPC1 O15118 4/20 0.37
RAB9A P51151 4/20 0.37
HTT P42858 3/20 0.37
MEN1 O00255 3/20 0.37
MAPT P10636 3/20 0.37
KMT2A Q03164 3/20 0.37
CYP1A2 P05177 1/20 0.37
LGMN Q99538 1/20 0.37
KDM4E B2RXH2 3/20 0.36
ALOX15 P16050 2/20 0.36
HSD17B10 Q99714 2/20 0.36
TP53 P04637 2/20 0.36
USP2 O75604 1/20 0.36
MAPK1 P28482 1/20 0.36
POLB P06746 1/20 0.36
AR P10275 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1608105 0.81 HRH3 (0.33) LMNAALDH1A1NPC1RAB9AHTT
SCHEMBL3595162 0.78 ADRA2C (0.39) ALDH1A1HTTMAPTKMT2AKDM4E
SCHEMBL1606819 0.76 ADRB1 (0.41)
SCHEMBL15415811 0.69 HTT (0.51) ALDH1A1HTTMEN1KMT2AALOX15
SCHEMBL4510267 0.65 LMNA (0.42) LMNAALDH1A1NPC1RAB9AHTT
SCHEMBL9093746 0.65 LMNA (0.71) LMNAEP300KAT2BALDH1A1NPC1
SCHEMBL189494 0.64 LMNA (0.50) LMNAALDH1A1NPC1RAB9AHTT
SCHEMBL8410646 0.64 LMNA (0.41) LMNAALDH1A1NPC1RAB9AHTT
SCHEMBL330110 0.62 LMNA (0.49) LMNAALDH1A1NPC1RAB9AMAPT
SCHEMBL3572619 0.62 MAPT (0.40) LMNAALDH1A1NPC1RAB9AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8518975-B2 Gamma secretase modulators Merck Sharp + Dohme Corp. (US) 2013-08-27 US disclosed
US-20110082153-A1 GAMMA SECRETASE MODULATORS SCHERING CORPORATION 2011-04-07 US disclosed
EP-2200990-A1 GAMMA SECRETASE MODULATORS SCHERING CORPORATION (US) 2010-06-30 EP disclosed
WO-2009032277-A1 GAMMA SECRETASE MODULATORS SCHERING CORPORATION (US) 2009-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110082153-A1 GAMMA SECRETASE MODULATORS BACE1, BACE2, PSEN1 LMNA 1968/4885EP300 1060/4885KAT2B 2190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.